학술논문

Phase 1 trial of the adenosine A2A receptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A2A receptor within the tumor.
Document Type
Journal
Source
JOURNAL OF CLINICAL ONCOLOGY; MAY 20 2021, 39 15, 2p. Supplement: S
Subject
Language
English
ISSN
15277755